Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

BACKGROUND: The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nmCSPC. In addition, the immunologic impact of enza...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Madan, Ravi A, Karzai, Fatima, Donahue, Renee N, Al-Harthy, Munjid, Bilusic, Marijo, Rosner, Inger I, Singh, Harpreet, Arlen, Philip M, Theoret, Marc R, Marté, Jennifer L, Cordes, Lisa, Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Owens, Helen, Lochrin, Sarah E, Chau, Cindy H, Steinberg, Seth, Figg, William Douglas, Dahut, William, Schlom, Jeffrey, Gulley, James L
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934713/
https://ncbi.nlm.nih.gov/pubmed/33664086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001556
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados